GSK’s Bepirovirsen Accelerates Towards Approval

GlaxoSmithKline (GB:GSK) has released an update.

GlaxoSmithKline’s investigational drug, bepirovirsen, has received SENKU designation in Japan, potentially speeding up its approval process for treating chronic hepatitis B. This follows its earlier US FDA Fast Track designation, showcasing the treatment’s promising trial results and its role in addressing a significant unmet medical need. Bepirovirsen, an antisense oligonucleotide, is currently undergoing phase III trials and is the sole agent showing potential for a functional cure in combination with existing oral treatments.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.